John McKew C.'s most recent trade in Lumos Pharma Inc was a trade of 3,407 Common Stock done at an average price of $1.9 . Disclosure was reported to the exchange on Aug. 6, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.89 per share. | 06 Aug 2024 | 3,407 | 12,653 (0%) | 0% | 1.9 | 6,426 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.79 per share. | 01 Aug 2024 | 1,593 | 16,060 (0%) | 0% | 1.8 | 2,851 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.78 per share. | 01 Apr 2024 | 2,214 | 17,153 (0%) | 0% | 2.8 | 6,144 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 2.84 per share. | 01 Apr 2024 | 2,000 | 20,403 (0%) | 0% | 2.8 | 5,680 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.84 per share. | 01 Apr 2024 | 1,036 | 19,367 (0%) | 0% | 2.8 | 2,942 | Common Stock |
| Lumos Pharma Inc | John McKew C. | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.03 per share. | 06 Feb 2024 | 438 | 18,403 (0%) | 0% | 3.0 | 1,328 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. | 01 Feb 2024 | 366 | 18,841 (0%) | 0% | 3.0 | 1,102 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.20 per share. | 01 Aug 2023 | 3,407 | 18,707 (0%) | 0% | 3.2 | 10,919 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.28 per share. | 01 Aug 2023 | 1,593 | 22,114 (0%) | 0% | 3.3 | 5,225 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.27 per share. | 01 Apr 2023 | 2,214 | 23,207 (0%) | 0% | 3.3 | 7,240 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.31 per share. | 01 Apr 2023 | 1,036 | 25,421 (0%) | 0% | 3.3 | 3,429 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 3.52 per share. | 01 Feb 2023 | 2,000 | 27,102 (0%) | 0% | 3.5 | 7,040 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.53 per share. | 01 Feb 2023 | 439 | 26,457 (0%) | 0% | 3.5 | 1,550 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.52 per share. | 01 Feb 2023 | 206 | 26,896 (0%) | 0% | 3.5 | 725 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.11 per share. | 01 Aug 2022 | 3,407 | 24,602 (0%) | 0% | 8.1 | 27,631 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.17 per share. | 01 Aug 2022 | 1,593 | 28,009 (0%) | 0% | 8.2 | 13,015 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.62 per share. | 06 Jun 2022 | 169 | 29,102 (0%) | 0% | 7.6 | 1,288 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.32 per share. | 01 Apr 2022 | 2,214 | 29,271 (0%) | 0% | 8.3 | 18,420 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.23 per share. | 01 Apr 2022 | 1,036 | 31,485 (0%) | 0% | 9.2 | 9,562 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 10.02 per share. | 01 Feb 2022 | 1,500 | 32,621 (0%) | 0% | 10.0 | 15,030 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.02 per share. | 01 Feb 2022 | 100 | 32,521 (0%) | 0% | 10.0 | 1,002 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2021 | 20,000 | 33,226 (0%) | 0% | 0 | Common Stock | |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.25 per share. | 01 Apr 2021 | 1,036 | 13,226 (0%) | 0% | 12.3 | 12,691 | Common Stock |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 33,175 | 33,175 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | John C. McKew | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 1,078 | 14,262 (0%) | 0% | 0 | Common Stock |